In this sense, based on the favorable results observed with the use of Bruton tyrosine kinase (BTK) inhibitors in R/R MCL patients [30,31,32,33], new studies have recently been conducted to incorporate these agents into primary MCL therapeutic regimens. Here, BTK is linked to mantle cell lymphoma.